ALX Oncology Holdings Future Growth
Future criteria checks 0/6
ALX Oncology Holdings is forecast to grow earnings and revenue by 4.4% and 85.7% per annum respectively. EPS is expected to grow by 20.5% per annum. Return on equity is forecast to be -226.5% in 3 years.
Key information
4.4%
Earnings growth rate
20.5%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | 85.7% |
| Future return on equity | -226.5% |
| Analyst coverage | Low |
| Last updated | 19 Dec 2024 |
Recent future growth updates
Recent updates
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
Sep 12ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
Jun 27ALX Oncology: Trying To Justify The Hype
Apr 18Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?
Mar 12
ALX Oncology GAAP EPS of -$0.81 misses by $0.18
Aug 08ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer
Aug 01ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer
Jun 29ALX Oncology Is Turning Into An Also-Ran In Anti-CD47
Feb 15ALX Oncology Stock: Attractive After Recent Data And Slump In Price
Nov 30ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space
Sep 08Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation
Jul 08Dosing underway in ALX Oncology's ALX148 combo study in head and neck cancer
May 10We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate
Mar 25Here's What ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) Shareholder Ownership Structure Looks Like
Feb 01
ALX Oncology: All Their Eggs In The Proverbial Basket
Jan 07Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3 | -180 | -170 | -174 | 4 |
| 12/31/2025 | N/A | -150 | -104 | -138 | 5 |
| 12/31/2024 | N/A | -143 | -23 | -149 | 5 |
| 9/30/2024 | N/A | -151 | -130 | -130 | N/A |
| 6/30/2024 | N/A | -171 | -134 | -135 | N/A |
| 3/31/2024 | N/A | -166 | -141 | -140 | N/A |
| 12/31/2023 | N/A | -161 | -132 | -130 | N/A |
| 9/30/2023 | N/A | -146 | -113 | -111 | N/A |
| 6/30/2023 | N/A | -130 | -114 | -111 | N/A |
| 3/31/2023 | N/A | -129 | -98 | -96 | N/A |
| 12/31/2022 | N/A | -123 | -91 | -89 | N/A |
| 9/30/2022 | N/A | -121 | -92 | -86 | N/A |
| 6/30/2022 | N/A | -110 | -86 | -80 | N/A |
| 3/31/2022 | N/A | -94 | -89 | -84 | N/A |
| 12/31/2021 | N/A | -83 | -73 | -68 | N/A |
| 9/30/2021 | N/A | -74 | -65 | -64 | N/A |
| 6/30/2021 | N/A | -60 | -49 | -49 | N/A |
| 3/31/2021 | 1 | -58 | -34 | -34 | N/A |
| 12/31/2020 | 1 | -51 | -38 | -38 | N/A |
| 9/30/2020 | 2 | -41 | -28 | -28 | N/A |
| 6/30/2020 | 4 | -34 | -21 | -21 | N/A |
| 3/31/2020 | 4 | -26 | -20 | -19 | N/A |
| 12/31/2019 | 5 | -23 | -15 | -14 | N/A |
| 12/31/2018 | 2 | -17 | -14 | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALXO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALXO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALXO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALXO is forecast to have no revenue next year.
High Growth Revenue: ALXO is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALXO is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 02:09 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ALX Oncology Holdings Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alethia Young | Cantor Fitzgerald & Co. |
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Martin Auster | Credit Suisse |